A plurality of members of two committees that advise the FDA on medications has voted to recommend that the agency remove rosiglitazone, which is marketed as Avandia, from the market because the diabetes drug has been linked to an increased risk for cardiovascular events.
Creating memories for families by sharing information relating to children and parents with regard to activities, products, school, home and more.
FDA Committees Critical of Avandia
- Login or register to post comments
- Feed: Health of the Public
- Original article